Portfolia — 2020 Investments

2 investments dated 2020 · listed companies and verified rows first · show all

NX Prenatalnxprenatal.comApr 2020SEC filingmedium confidence

NX Prenatal is a molecular diagnostics company developing exosome-based liquid biopsy assays that detect adverse pregnancy conditions such as preterm birth, preeclampsia, and placenta accreta.

BiotechDigital HealthFemTechHealthtechLouisville, US

Paul Kortschak(Chief Executive Officer)GAIL PAGE(Executive Officer, Director)BRIAN BROHMAN(Executive Officer, Director)ROBERT SAUNDERS(Director)KEVIN BRAMER(Director)ALAN MACK(Director)

Board seat Mary Lake Polan· per SEC Form D · $6M raise · filed Aug 2021

Co-investorsBelle Impact Fund Keyhorse Capital Mindshift Capital Solas BioVentures Golden Seeds

Mercy BioAnalyticsmercybio.com inNov 2020

Mercy BioAnalytics develops diagnostic tests for early cancer detection using advanced proteomics and genomics technologies.

BiotechDigital HealthHealthtechMedical DevicesNatick, US

Paul Blavin(Co-Founder & Vice Chairman)in Stanley Lapidus(Director)inDawn Mattoon, PhD(Chief Executive Officer)Joseph Sedlak(Executive Officer, Director)

Board Paul Meister(Director)Sonja Hoel Perkins(Director)in

Co-investorsAvestria Ventures Hatteras Venture Partners iSelect Fund Mindshift Capital Novalis LifeSciences Sozo Ventures +2 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.